tert-Butyl 4-(4-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate

Catalog No. :
ACNZMB685
CAS No. :
668484-15-9
Molecular Formula :
C14H19F3N4O2
Molecular Weight :
332.33

IUPAC Name:tert-butyl 4-(4-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(4-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$176.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate
Molecular FormulaC14H19F3N4O2
Molecular Weight332.33
SMILESO=C(N1CCN(C2=NC=CC(C(F)(F)F)=N2)CC1)OC(C)(C)C
InChI KeyZNQYZSDVVTXOOR-UHFFFAOYSA-N
Synonym1-Piperazinecarboxylic acid, 4-[4-(trifluoromethyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester;tert-Butyl 4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazine-1-carboxylate
CAS No.668484-15-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACNZMB685 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNZMB685 route product structure diagram
    ACNZMB685668484-15-9
Inquiry

2. ACNZMB685 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACREJV018 route compound structure diagram
    ACREJV018179756-91-3 In Stock
  4. Then
  5. ACNZMB685 route product structure diagram
    ACNZMB685668484-15-9
Inquiry

Comments (0)